A Conversation with Kuldip Dave of the Michael J. Fox Foundation

April 2, 2012 - PRLog -- Needham, MA – Kuldip Dave, Ph.D, Associate Director, Research Programs, The Michael J. Fox Foundation for Parkinson's Research is set to give the keynote address at the Second Annual Targeting Parkinson’s Disease symposia.  The symposia, taking place June 4-5 in Philadelphia, will address both disease modification and therapeutic development for levodopa induced dyskinesia, an unmet medical need within Parkinson’s treatment, and other PD-treatment symptoms. Advances in target identification, biomarker development, and genetics (such as LRKK2 and alpha-synuclein) will also be discussed.

Conference Producer Kathleen Skaare recently had the opportunity to discuss the keynote address, as well as the work Kuldip is performing with the MJFF via teleconference, available as a complimentary podcast download at WorldPharmaCongress.com/Targeting-Parkinsons-Disease.

“The Michael J. Fox Foundation, as well as foundations like it, is critical to advancing the path to a cure for Parkinson’s Disease. Kuldip’s work on the drug repositioning initiatives echoes a current trend in the pharmaceutical industry; also, the Foundation’s support of seeking treatment for symptoms of PD may help currently affected PD patients in their lifetimes,” said Ms. Skaare.

The podcast runs about fifteen minutes, and is available free of charge at the above website.  

About Kuldip Dave:

Kuldip D. Dave joined the Michael J. Fox Foundation in July 2010.  Dr. Dave earned his undergraduate degree from Rutgers University and his graduate degree in pharmacology and physiology at Drexel University College of Medicine.  His thesis work focused on serotonin and dopamine receptor regulation of motor behavior mainly in the frontal cortex and the hippocampus.  He completed his postdoctoral fellowship at Adolor Corporation, studying mu/delta opioid receptor regulation of pain and inflammation in the spinal cord.  He went on to work in the Women's Health group at Wyeth Research, where he investigated ovarian hormonal regulation of anxiety, depression and sexual dysfunction.  He has extensive drug-discovery experience developing in vivo, ex vivo, and in vitro disease models as well as investigating receptor regulation, signal transduction, neurotransmitter release, biomarker identification and animal behavior.

For more information about the Michael J. Fox Foundation, visit http://www.michaeljfox.org

# # #

Since 1992, Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations.